Avalo Therapeutics vs Vyome
AVTX and HIND side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AVTX and HIND compare
Avalo Therapeutics is the larger company, worth 38 times as much as Vyome ($416M against $11.1M).
Avalo Therapeutics scores higher on the StockData Score (8 against 1 for Vyome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AVTX | HIND |
|---|---|---|
| Size and price | ||
| Market cap | $416M | $11.1M |
| Share price | $7.76 | $1.58 |
| Change, 1 year | −49.7% | −70.3% |
| Change, 5 years | −99.9% | −100.0% |
| Beta (5Y) | 0.87 | 1.56 |
| Employees | 23 | 18 |
| StockData Score | ||
| Total score | 8 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 72.4× |
| P/B | 1.0× | – |
| Growth | ||
| Revenue growth (TTM) | – | −55.6% |
| Revenue growth, 5Y average | −61.2% | −51.0% (better) |
| Profitability | ||
| Gross margin | – | 50.4% |
| Operating margin | – | −2854% |
| Net margin | – | −2456% |
| Return on equity | −33.6% (better) | −149% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −229.3× |
| Current ratio | 16.63 (better) | 3.68 |
| Altman Z-score | 4.32 (better) | −12.31 |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −53.1% |
| Shareholder yield | 0.00% (better) | −53.1% |
| Ownership | ||
| Held by institutions | 135% | 2.0% |
| Held by insiders | 0.71% | 6.8% |
| Insider net buying, 12 months | −$8.3M | – |
| Short interest, % of float | 16.7% | 0.28% |
Go deeper
- AVTX stock overview
- AVTX income statement
- AVTX valuation and score
- HIND stock overview
- HIND income statement
- HIND valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.